Navigation Links
Clinical Study Shows Sustamine(TM) L-Alanyl-L-Glutamine Increases Performance in Endurance, Exercise and Activity
Date:2/11/2010

NEW YORK, Feb. 11 /PRNewswire/ -- A clinical study by Dr. Jay Hoffman, PhD, professor and chair of the Department of Health and Exercise Science at the College of New Jersey, has shown Sustamine™ L-Alanyl-L-Glutamine, increases performance in endurance exercise and activity. The study was published on February 3, 2010, in the Journal of the International Society of Sports Nutrition (JISSN), a peer-reviewed journal covering various aspects of sports nutrition, supplementation, exercise metabolism, and/or scientific policies related to sports nutrition.

(Logo: http://www.newscom.com/cgi-bin/prnh/20100211/SF53296LOGO)

The data published in the Journal of ISSN shows:

  • Significant performance reduction occurred when exercising to exhaustion in subjects' hypohydrated to 2.5% of body mass. 
  • When subjects ingested the Sustamine™ supplement during the rehydration period the magnitude of performance reduction was significantly less compared to the dehydrated condition. 
  • Water alone did not appear to significantly off-set the performance reduction.

The study showed the efficacy of Sustamine L-Alanyl-L-Glutamine ingestion during Hydration Stress under intense exercise. The clinical study covered the ability of Sustamine L-Alanyl-L-Glutamine to enhance fluid regulation in healthy, active individuals in relation to both endurance and high intensity exercise. Further discussion focuses on the potential ergogenic benefit that Sustamine™ has under these exercise and hydration stresses.  The role that this dipeptide has on the inflammatory, immune and recovery responses to these stresses was also examined.

Sustamine™ is the only GRAS (Generally Recognized As Safe) form of L-Alanyl-L-Glutamine for a variety of food, beverage and healthcare applications. It appears to increase electrolyte and fluid uptake across the intestines by increasing ion transport through an enhanced signaling pathway within the intestinal mucosal cells. Its implications for exercise are enhancement of fluid regulation during prolonged exercise in the heat, maintaining or enhancing performance during a hydration/heat stress, and enhancing recovery from exercise by modulating immune, inflammatory and oxidative stress responses to physical activity. 

Sustamine™, manufactured by Kyowa Hakko Bio Co. Ltd., is considered a "high-tech" amino acid dipeptide that promotes muscle rehydration, recovery and can be used as a source for energy refueling. Produced by a novel and cost effective patented fermentation technology, Sustamine™ L-Alanyl-L-Glutamine is available in powder form and is water-soluble into a clear solution. It is also odorless and tasteless.

Additional Sustamine™ highlights include:

  1. Patent pending for improved endurance performance
  2. Only stable form of glutamine for solutions or ready to drink beverages
  3. Stable in beverages with broad pH ranges
  4. Stable in beverages for over one year at room temperature

Dr. Hoffman's November 2009 SupplySide West seminar, Efficacy of Sustamine™ L-Alanyl-L-Glutamine Ingestion During Hydration Stress Under Intense Exercise is available for viewing at http://www.kyowa-usa.com/multimedia/nutritionals/.

Kyowa Hakko Bio is an international health ingredients manufacturer and world leader in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. Kyowa is the maker of branded ingredients including Cognizin® Citicoline, Hydrafend™ Hyaluronic Acid, Lumistor® L-Hydroxyproline, Setria® Glutathione, Kyowa CoQ10™ as well as Sustamine™ L-Alanyl-L-Glutamine.

Kyowa offers manufacturers and formulators one of the industry's most extensive lines of over 50 amino acids and related compounds, including D-Amino acids and branch-chain amino acids, as well as nucleic acids, bio-products and fine chemicals.

Additional information on Sustamine™ L-Alanyl-L-Glutamine can be found online at www.Kyowa-USA.com or contact Kyowa at Info@Kyowa-USA.com or

212-319-5353.

SOURCE Kyowa Hakko

RELATED LINKS
http://www.kyowa-usa.com
http://www.Sustamine.com

'/>"/>

SOURCE Kyowa Hakko
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Scientists from Silicon Biosystems Menarini today ... door to genetic analysis of previously preserved tumor ... isolate with 100 percent purity. Utilizing the com­pany,s ... various stages of development, the researchers were able ... are clinically relevant, and may change the way ...
(Date:2/11/2016)... 11, 2016  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ... made at the 38th annual John A. Boswick ... which is being held February 14-18, 2016 in ... latest advancements in wound healing, burn care, and infection ... Australian-New Zealand Burns Association, Academy of Physicians in Wound ...
(Date:2/11/2016)... 2016  Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced ... a Controlled Equity Offering SM Sales Agreement with ... Macaluso , Chairman and CEO, stated "During our most ... currently raising money and that we have enough money ... still complete all of our current objectives and nothing ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... 11, 2016 , ... According to an article published February 1st ... dietary supplement, is being recalled due to the discovery that it contains dangerous adulterants. ... a single supplement on the market proven to help people safety lose excess weight, ...
(Date:2/11/2016)... ... 11, 2016 , ... Dr. Sadati’s recent feature in Allure ... with performing procedures, the magazine also highlights that Dr. Sadati has pioneered new ... the most common procedures he performs is his natural facelift. “As people age, ...
(Date:2/11/2016)... ... 11, 2016 , ... The president released a FY 2017 budget request on ... more of the cost burden to military beneficiaries. , MOAA’s president, retired Air ... budget as including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. , ...
(Date:2/11/2016)... Irving, Texas (PRWEB) , ... February 11, 2016 ... ... for plastic surgery, dermatology and women’s health, is pleased to announce the promotions ... Practice Development Partners sales team, Steve Catone to executive vice president of North ...
(Date:2/11/2016)... ... February 11, 2016 , ... The Commission for ... the Board of Commissioners. Individuals interested in volunteer board service are encouraged to ... clinical practice settings and across allied health to contribute to its mission and ...
Breaking Medicine News(10 mins):